hattime81
About
Adjuvant ruxolitinib treatments minimizes steroid-refractory cytokine-release affliction without having impairing chimeric antigen receptor-modified T-cell purpose.
Adjuvant ruxolitinib treatments minimizes steroid-refractory cytokine-release affliction without having impairing chimeric antigen receptor-modified T-cell purpose.